[
  {
    "ts": null,
    "headline": "3 Magnificent Growth Stocks to Buy in March",
    "summary": "Prosper Junior Bakiny (Eli Lilly): What's considered excellent revenue growth depends on the industry.  With that context in mind, consider that Eli Lilly's revenue growth has not dipped below 20% since mid-2023.",
    "url": "https://finnhub.io/api/news?id=b9e2ea71c875b99b34fdb720c216a37bf14fa2904bbfc4b0be137be181e6570e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741448460,
      "headline": "3 Magnificent Growth Stocks to Buy in March",
      "id": 133185017,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Prosper Junior Bakiny (Eli Lilly): What's considered excellent revenue growth depends on the industry.  With that context in mind, consider that Eli Lilly's revenue growth has not dipped below 20% since mid-2023.",
      "url": "https://finnhub.io/api/news?id=b9e2ea71c875b99b34fdb720c216a37bf14fa2904bbfc4b0be137be181e6570e"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS",
    "summary": "Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in moderate to severe atopic dermatitis (AD).",
    "url": "https://finnhub.io/api/news?id=fbbfb1eb2a7fd77209918912861331726ccd65b30c935eb30d33e850c1ee96a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741431600,
      "headline": "AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS",
      "id": 133185018,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in moderate to severe atopic dermatitis (AD).",
      "url": "https://finnhub.io/api/news?id=fbbfb1eb2a7fd77209918912861331726ccd65b30c935eb30d33e850c1ee96a2"
    }
  },
  {
    "ts": null,
    "headline": "A Major Market Rotation Is Likely Coming",
    "summary": "The market hasnât priced in several undervalued AI stocks. Read why these stocks could outperform tech in the next market cycle.",
    "url": "https://finnhub.io/api/news?id=1c6d6c18c949ac77909a5de381dc8c854be2e40d9ba7d6a9459ec91dbff1bf7c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741431600,
      "headline": "A Major Market Rotation Is Likely Coming",
      "id": 133107060,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2151843291/image_2151843291.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "The market hasnât priced in several undervalued AI stocks. Read why these stocks could outperform tech in the next market cycle.",
      "url": "https://finnhub.io/api/news?id=1c6d6c18c949ac77909a5de381dc8c854be2e40d9ba7d6a9459ec91dbff1bf7c"
    }
  }
]